Progress of Neoadjuvant Therapy Combined with Surgery in Non-small Cell Lung Cancer

VernacularTitle:非小细胞肺癌新辅助治疗联合外科治疗的进展
Author: WANG YAQI ¹ ; WANG XING ; YAN SHI ; YANG YUE ; WU NAN
Author Information

1. 100142 北京,北京大学肿瘤医院暨北京市肿瘤防治研究所胸外二科,恶性肿瘤发病机制及转化研究教育部重点实验室
Keywords: Lung neoplasms; Neoadjuvant therapy; Surgery
From: Chinese Journal of Lung Cancer 2017;20(5):352-360
CountryChina
Language:Chinese
Abstract: Background and objective Lung cancer is the leading form of cancer in terms of both incidence and cancer-related deaths. For patients with resectable Ⅲa/N2 non-small cell lung cancer (NSCLC), guidelines in and abroad recommend multidisciplinary team treatment, including surgery and chemotherapy, radiotherapy or other comprehensive treatment. Newly published evidences prove that neoadjuvant therapy can improve outcomes of NSCLC patients significantly, with advangtages in tolerability and compliance medication. Neoadjuvant therapy has been adopted mainly in locally advanced NSCLC, especially in stages Ⅲa/N2 patients, and chemotherapy of 2-4 cycles has become the basic pattern. Neoadjuvant therapy does not increase the concomitant complications of chemotherapy and surgery. However, challenges still exist in deter-mining subsequent surgical timing, approach and extent of resection.